Gilead Sciences, known for its work in HIV, oncology, and viral diseases, is expanding its U.S. footprint with new investments in manufacturing and research. In recent Gilead news, the company has begun construction on a major facility at its Foster City headquarters.
This update also covers Gilead’s latest infrastructure projects, developments in its drug pipeline, sales performance, and legal issues.
Latest Gilead News: Gilead Begins Construction on Foster City Facility Under $32B Manufacturing Investment
Gilead Sciences has started construction on a new 180,000-square-foot pharmaceutical development and manufacturing facility at its headquarters in Foster City, California.
This five-story site is part of the company’s $32 billion investment in expanding U.S.-based operations through 2030.
It will also support small molecule production and advanced therapy development, according to Gilead CEO Daniel O’Day.
In addition to the Foster City site, Gilead is moving forward with two other California-based projects: a research building focused on accelerating preclinical work, and a biologics manufacturing facility designed to scale production of antibody and cell therapies.
Gilead projects the investment will create over 3,000 direct and indirect jobs and contribute roughly $43 billion in economic value to the U.S. over the next five years. The new sites are also expected to be phased in through the end of the decade.
Gilead News: Additional $11 Billion Investments In U.S. Manufacturing and Research
Gilead Sciences plans to invest another $11 billion to grow its manufacturing and research work in the U.S. The company shared this update on May 7, adding to its earlier plan of spending $21 billion through 2030.
This money will go toward new technology, building three new facilities, and improving three existing ones. Gilead’s decision comes as the government continues to push drugmakers to shift more of their production to the U.S. The administration has also started looking into drug imports, which could lead to new trade limits.
Gilead says the added investment will help create at least 800 direct jobs and support over 2,200 other jobs by 2028. Over the next five years, the company estimates its spending will add $43 billion in value to the U.S. economy.
Gilead News: Q1 Earnings Slight Beat Expectations, Mixed Analyst Opinions On Stock Performance
On April 25, Gilead shared its results for the first quarter of 2025. The company said it started the year strong thanks to solid performance in sales and research and careful cost control.
Revenue stayed flat overall. However, higher sales of HIV and liver disease treatments helped make up for weaker cancer drug sales. Gilead also kept spending in check, which helped balance out the slower areas.
Still, the company’s stock slipped about 3% in after-hours trading, landing at $102.75. Adjusted earnings per share reached $1.81, just above the $1.79 average that analysts expected. Then, revenue came in at $6.7 billion, slightly below the $6.8 billion forecast.
Some analysts saw promising signs in the steady sales, strong earnings, and lower costs. But others say future growth may depend on whether the FDA gives the green light to Gilead’s HIV prevention drug, lenacapavir, without delays.
FDA Accepts Gilead’s HIV Prevention Drug Applications for Twice-Yearly Lenacapavir
On February 18, 2025, the U.S. Food and Drug Administration (FDA) accepted Gilead’s application to review lenacapavir, a long-acting injection given twice a year to help prevent HIV. The drug is being reviewed as a form of pre-exposure protection, also known as PrEP.
The FDA plans to make a decision by June 19 on whether to approve the drug.
“We are one step closer to introducing the first-ever twice-yearly HIV prevention choice that could, if approved, help transform the landscape for individuals who need or want additional prevention options that better fit into their lives,” said Dietmar Berger, MD, PhD, Chief Medical Officer at Gilead.
Berger added, “We’re excited about the potential of lenacapavir to make a real difference in HIV prevention in the U.S. and around the world, supporting the broader goal of ending the HIV epidemic for everyone, everywhere.”
Gilead News: Progress In Phase 3 Trial of Trodelvy-Keytruda Combo
Gilead shared new results from a late-stage study of its cancer drug Trodelvy on April 21. When combined with Merck’s Keytruda, the treatment helped slow the growth of an aggressive form of breast cancer.
The Phase 3 trial looked at 443 patients with advanced triple-negative breast cancer whose tumors showed PD-L1, a protein targeted by drugs like Keytruda. The study compared the Trodelvy-Keytruda mix to the usual treatment of chemotherapy plus Keytruda.
Gilead said the combination showed signs of improving overall survival, though more time and follow-up with patients are needed to confirm that benefit.
“The findings are statistically significant and clinically meaningful. This is a study that could potentially change the standard of care,” said Dietmar Berger.
Gilead Legal Affairs: $202 Million Settlement & Ongoing Litigation
Gilead Sciences has agreed to pay $202 million to settle a whistleblower case that accused the company of giving illegal payments to doctors who prescribed its HIV medicines.
The U.S. Attorney in Manhattan, Jay Clayton, said Gilead broke the law by causing Medicare, Medicaid, and other programs to cover prescriptions tied to its speaker events. These programs involved paying doctors to attend or speak at events that promoted the company’s drugs.
From 2011 to 2017, Gilead reportedly spent over $23 million on speaker fees, expensive dinners, and trips to places like Hawaii and New Orleans for hundreds of healthcare providers. In some cases, doctors repeatedly attended talks on the same topic. One group of ten doctors from Manhattan showed up together at around 384 dinners, according to court documents.
The drugs involved include Biktarvy, Complera, Descovy, Genvoya, Odefsey, and Stribild.
“With this settlement, Gilead has taken responsibility for its conduct. The message is clear: Companies that illegally drain taxpayer dollars from federal healthcare programs will be held accountable,” Clayton said
Gilead said it agreed to settle to avoid a lengthy and costly legal fight. The company had already put aside funds for the settlement last year.
At the same time, Gilead is dealing with a separate legal case involving patients who claim the company’s HIV treatments caused bone and kidney problems. After some of the plaintiffs’ lawyers stepped away from the case, Gilead asked the court to dismiss those who hadn’t found new legal representation or filed to represent themselves. A California judge partly agreed and set a meeting to go over the next steps.
What Gilead’s Latest Moves Mean for Biotech, Patients, and Investors
Gilead’s expanded manufacturing footprint signals a long-term commitment to scaling production and accelerating development across its therapeutic portfolio.
As construction progresses in Foster City and its other California sites, the company is positioning itself to support more complex therapies with shorter turnaround times.
While investors continue to monitor regulatory approvals and ongoing legal matters, the focus remains on how these developments could influence Gilead’s pipeline and commercial strategy.
To stay updated on Gilead news and the latest developments about business, finance, and biotech companies, subscribe to Financial Daily Update today.
Latest News
-
HappyRobot News: $44M Funding, Supply Chain Award & Venture Backing
-
Figure Technologies Seeks $4.1B IPO, Expands Lending Services
-
Forever 21 News: Revival, U.S. Liquidation, & Global Outlook
-
EchoStar News: AT&T Spectrum Sale, MDA Space LEO Project & Q2 Earnings
-
Klarna News: IPO Valuation, U.S. BNPL Growth, & Earnings
-
Jefferies Raises S&P 500 Target & Urges Banker Teamwork
-
Bavarian Nordic Surpasses Q2 Forecast & Completes Priority Review Voucher Deal
Updated September 3, 2025
